oalib

Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99

Submit

Any time

2019 ( 145 )

2018 ( 364 )

2017 ( 379 )

2016 ( 415 )

Custom range...

Search Results: 1 - 10 of 208395 matches for " Gallelli L "
All listed articles are free for downloading (OA Articles)
Page 1 /208395
Display every page Item
Update on optimal use of omalizumab in management of asthma
Pelaia G,Gallelli L,Renda T,Romeo P
Journal of Asthma and Allergy , 2011,
Abstract: Girolamo Pelaia1, Luca Gallelli1, Teresa Renda1, Pasquale Romeo1, Maria Teresa Busceti1, Rosa Daniela Grembiale1, Rosario Maselli1, Serafino Antonio Marsico2, Alessandro Vatrella31Department of Experimental and Clinical Medicine, University Magna Gr cia of Catanzaro, Catanzaro; 2Department of Cardiothoracic and Respiratory Sciences, Second University of Naples, Naples; 3Department of Respiratory Medicine, University of Salerno, Salerno, ItalyAbstract: Omalizumab is a humanized monoclonal anti-IgE antibody recently approved for the treatment of severe allergic asthma. This drug inhibits allergic responses by binding to serum IgE, thus preventing interaction with cellular IgE receptors. Omalizumab is also capable of downregulating the expression of high affinity IgE receptors on inflammatory cells, as well as the numbers of eosinophils in both blood and induced sputum. The clinical effects of omalizumab include improvements in respiratory symptoms and quality of life, paralleled by a reduction of asthma exacerbations, emergency room visits, and use of systemic corticosteroids and rescue bronchodilators. Omalizumab is relatively well-tolerated, and only rarely induces anaphylactic reactions. Therefore, this drug represents a valid option as add-on therapy for patients with severe persistent allergic asthma inadequately controlled by high doses of standard inhaled treatments.Keywords: omalizumab, anti-IgE, severe asthma
Update on optimal use of omalizumab in management of asthma
Pelaia G, Gallelli L, Renda T, Romeo P, Busceti MT, Grembiale RD, Maselli R, Marsico SA, Vatrella A
Journal of Asthma and Allergy , 2011, DOI: http://dx.doi.org/10.2147/JAA.S14520
Abstract: ate on optimal use of omalizumab in management of asthma Review (6160) Total Article Views Authors: Pelaia G, Gallelli L, Renda T, Romeo P, Busceti MT, Grembiale RD, Maselli R, Marsico SA, Vatrella A Published Date June 2011 Volume 2011:4 Pages 49 - 59 DOI: http://dx.doi.org/10.2147/JAA.S14520 Girolamo Pelaia1, Luca Gallelli1, Teresa Renda1, Pasquale Romeo1, Maria Teresa Busceti1, Rosa Daniela Grembiale1, Rosario Maselli1, Serafino Antonio Marsico2, Alessandro Vatrella3 1Department of Experimental and Clinical Medicine, University Magna Gr cia of Catanzaro, Catanzaro; 2Department of Cardiothoracic and Respiratory Sciences, Second University of Naples, Naples; 3Department of Respiratory Medicine, University of Salerno, Salerno, Italy Abstract: Omalizumab is a humanized monoclonal anti-IgE antibody recently approved for the treatment of severe allergic asthma. This drug inhibits allergic responses by binding to serum IgE, thus preventing interaction with cellular IgE receptors. Omalizumab is also capable of downregulating the expression of high affinity IgE receptors on inflammatory cells, as well as the numbers of eosinophils in both blood and induced sputum. The clinical effects of omalizumab include improvements in respiratory symptoms and quality of life, paralleled by a reduction of asthma exacerbations, emergency room visits, and use of systemic corticosteroids and rescue bronchodilators. Omalizumab is relatively well-tolerated, and only rarely induces anaphylactic reactions. Therefore, this drug represents a valid option as add-on therapy for patients with severe persistent allergic asthma inadequately controlled by high doses of standard inhaled treatments.
Asterixis as a Presentation of Cerebellar Ischemic Stroke
Antonio Siniscalchi,Luca Gallelli,Olindo Di Benedetto,Giovambattista De Sarro
Western Journal of Emergency Medicine : Integrating Emergency Care with Population Health , 2012,
Abstract: Asterixis is not yet considered a common neurological sign of cerebellum infarction, and the pathogenic mechanism for asterixis remains elusive. We report a 58-year-old male with moderate hypertension who presented to our emergency department for acute headache in both cervical and occipital regions of the left side. About 2 hours later the patient developed ipsilateral asterixis in the upper left limb; 3 days later the asterixis disappeared. Magnetic resonance imaging of the brain disclosed cerebellarinfarctions at the left superior cerebellar artery. In conclusion, we observed that a transitory asterixis associated with ipsilateral headache can be an initial clinical manifestation of ipsilateral cerebellar infarctions in the superior cerebellar artery area.
Simvastatin Action Is Not Related to HDAC2 Expression in Non-Small Cell Lung Cancer (NSCLC)  [PDF]
Gallelli Luca, Falcone Daniela, Perri Mariarita, Erika Cione, Pelaia Girolamo, Mesuraca Maria, Terracciano Rosa, Spaziano Giuseppe, D’Agostino Bruno, Navarra Michele, Savino Rocco
Journal of Cancer Therapy (JCT) , 2016, DOI: 10.4236/jct.2016.712091
Abstract: In this study, we lowered the expression of HDAC2 protein, to evaluate the effects of simvastatin on the biochemical pathways involved in inflammatory and metastatic response. The model used is the non-small cell lung cancer line (GLC-82). Trypan blue staining for assessing vital cell number to be seed and MTT assay was used as cell proliferation test. Lentivus for HDAC2 was used to silence its mRNA. Western blotting analysis was used for protein extracts, and ELISA was done on culture media for cytokines (IL-6, IL-8 and TNF-alpha) release. Hydrogen peroxide (H2O2) was used to induce oxidative stress. Our results have shown that Lentivirus containing the shHDAC2 in GLC-82 cells was able to reduce protein expression of HDAC2. In the GLCshHDAC2 cell line obtained, H2O2 induced a significant increase in cytokines release and ERK1/2 phosphorylation (P < 0.01); a significant decrease of RECK activation (P < 0.01); a significant increased activation (P < 0.01) of both MMP-2 and MMP-9 and an increased
Interactions among Low Dose of Methotrexate and Drugs Used in the Treatment of Rheumatoid Arthritis
Marinella Patanè,Miriam Ciriaco,Serafina Chimirri,Francesco Ursini,Saverio Naty,Rosa Daniela Grembiale,Luca Gallelli,Giovambattista De Sarro,Emilio Russo
Advances in Pharmacological Sciences , 2013, DOI: 10.1155/2013/313858
Abstract: Methotrexate (MTX) is a nonbiological disease-modifying antirheumatic drug that has shown both a good control of clinical disease and a good safety. Usually drug-drug interactions (DDIs) represent the most limiting factor during the clinical management of any disease, in particular when several drugs are coadministered to treat the same disease. In this paper, we report the interactions among MTX and the other drugs commonly used in the management of rheumatoid arthritis. Using Medline, PubMed, Embase, Cochrane libraries, and Reference lists, we searched for the articles published until June 30, 2012, and we reported the most common DDIs between MTX and antirheumatic drugs. In particular, clinically relevant DDIs have been described during the treatment with MTX and NSAIDs, for example, diclofenac, indomethacin, or COX-2 inhibitors, and between MTX and prednisone or immunosuppressant drugs (e.g., leflunomide and cyclosporine). Finally, an increase in the risk of infections has been recorded during the combination treatment with MTX plus antitumor necrosis factor-α agents. In conclusion, during the treatment with MTX, DDIs play an important role in both the development of ADRs and therapeutic failure. 1. Introduction Rheumatoid arthritis (RA) is a chronic and autoimmune disease affecting about 1% of people, with the highest incidence between 40 and 70 years [1]. Drugs able to reduce inflammation and cells activation may be used in the management of RA. In particular, nonsteroidal anti-inflammatory drugs (NSAIDs) as well as immunosuppressive agents (i.e., glucocorticoids), disease-modifying antirheumatic drugs (DMARDs), and agents that are able to block the proinflammatory cytokine tumor necrosis factor-α (anti-TNF-α) may be used (Table 1). Table 1: Drugs used in the management of rheumatoid arthritis. NSAIDs, acting on cyclooxygenases, are able to control the inflammation and the clinical symptoms [2–4], but not the disease’s progression; their use as monotherapy for a long time is limited for the development of adverse drug reactions (ADRs) [5]. Glucocorticoids (e.g., dexamethasone and prednisone) are anti-inflammatory and immune suppressor agents that are able to reduce the inflammation and the progression of RA, through the inhibition of cytokines secretion and osteoclasts activation [6–15]. However, even if they represent a first-line treatment in patients with RA, their use is limited for the development of serious ADRs such as loss of bone mass, increased risk of fractures, infections, diabetes and hypertension [16–18]. The DMARDs group, includes
Computing Reachable Sets as Capture-Viability Kernels in Reverse Time  [PDF]
No?l Bonneuil
Applied Mathematics (AM) , 2012, DOI: 10.4236/am.2012.311219
Abstract: The set SF(x0;T) of states y reachable from a given state x0 at time T under a set-valued dynamic x’(t)∈F(x (t)) and under constraints x(t)∈K where K is a closed set, is also the capture-viability kernel of x0 at T in reverse time of the target {x0} while remaining in K. In dimension up to three, Saint-Pierre’s viability algorithm is well-adapted; for higher dimensions, Bonneuil’s viability algorithm is better suited. It is used on a large-dimensional example.
Three Dimensional Evolution of SN 1987A in a Self-Gravitating Disk  [PDF]
L. Zaninetti
International Journal of Astronomy and Astrophysics (IJAA) , 2013, DOI: 10.4236/ijaa.2013.32010
Abstract:

The introduction of an exponential or power law gradient in the interstellar medium (ISM) allows to produce an asymmetric evolution of the supernova remnant (SNR) when the framework of the thin layer approximation is adopted. Unfortunately both the exponential and power law gradients for the ISM do not have a well defined physical meaning. The physics conversely is well represented by an isothermal self-gravitating disk of particles whose velocity is everywhere Maxwellian. We derived a law of motion in the framework of the thin layer approximation with a control parameter of the swept mass. The photon’s losses, which are often neglected in the thin layer approximation, are modeled trough velocity dependence. The developed framework is applied to SNR 1987A and the three observed rings are simulated.

The Luminosity Function of Galaxies as Modeled by a Left Truncated Beta Distribution  [PDF]
L. Zaninetti
International Journal of Astronomy and Astrophysics (IJAA) , 2014, DOI: 10.4236/ijaa.2014.41013
Abstract: A first new luminosity function of galaxies can be built starting from a left truncated beta probability density function, which is characterized by four parameters. In the astrophysical conversion, the number of parameters increases by one, due to the addition of the overall density of galaxies. A second new galaxy luminosity function is built starting from a left truncated beta probability for the mass of galaxies once a simple nonlinear relationship between mass and luminosity is assumed; in this case the number of parameters is six because the overall density of galaxies and a parameter that regulates mass and luminosity are added. The two new galaxy luminosity functions with finite boundaries were tested on the Sloan Digital Sky Survey (SDSS) in five different bands; the results produce a better fit than the Schechter luminosity function in two of the five bands considered. A modified Schechter luminosity function with four parameters has been also analyzed.
On the Dark Matter’s Halo Theoretical Description  [PDF]
L. M. L. M. Chechin
Journal of Modern Physics (JMP) , 2012, DOI: 10.4236/jmp.2012.35052
Abstract: We argued that the standard field scalar potential couldn’t be widely used for getting the adequate galaxies’ curve lines and determining the profiles of dark matter their halo. For discovering the global properties of scalar fields that can describe the observable characteristics of dark matter on the cosmological space and time scales, we propose the simplest form of central symmetric potential celestial-mechanical type, i.e. U(φ) = –μ/φ. It was shown that this potential allows get rather satisfactorily dark matter profiles and rotational curves lines for dwarf galaxies. The good agreement with some previous results, based on the N-body simulation method, was pointed out. A new possibility of dwarf galaxies’ masses estimation was given, also.
Analytical Approximation to the Dynamics of a Binary Stars System with Time Depending Mass Variation  [PDF]
Gustavo V. López, Elkin L. López
Journal of Applied Mathematics and Physics (JAMP) , 2018, DOI: 10.4236/jamp.2018.63053
Abstract: We study the classical dynamics of binary stars when there is an interchange of mass between them. Assuming that one of the stars is more massive than others, the dynamics of the lighter one is analyzed as a function of its time depending mass variation. Within our approximations and models for mass transference, we obtain a general result which establishes that if the lightest star looses mass, its period increases. If the lightest star wins mass, its period decreases.
Page 1 /208395
Display every page Item


Home
Copyright © 2008-2017 Open Access Library. All rights reserved.